K-STREET TRACKER
FOLLOW THE MONEY INTO THE SWAMP
Every federal lobbying filing tagged with a public-company ticker — who is spending, which firms they hire, and which members trade right around the filing.
Filings tracked
19,882
thru 2026-05-08
Total reported $
$2.7B
disclosed lobbying
Distinct clients
2,220
paying companies
Tickers targeted
1,207
public companies
💸 Top Spending Clients
| # | Client | Filings | Total $ |
|---|---|---|---|
| 1 |  PFIZER INC.PFE | 47 | $46.8M |
| 2 |  GENERAL MOTORS COMPANYGM | 61 | $46.8M |
| 3 |  META PLATFORMS INC. AND VARIOUS SUBSIDIARIESMETA | 12 | $44.9M |
| 4 | VISA INC.V | 45 | $37.7M |
| 5 |  AMAZON.COM SERVICES LLCAMZN | 36 | $32.8M |
| 6 |  LOCKHEED MARTIN CORPORATIONLMT | 73 | $29.0M |
| 7 |  FEDEX CORPORATIONFDX | 69 | $27.8M |
| 8 |  ELI LILLY AND COMPANYLLY | 56 | $27.1M |
| 9 |  ALTRIA CLIENT SERVICES LLCMO | 142 | $25.2M |
| 10 |  AMGEN INCAMGN | 19 | $24.9M |
| 11 |  COMCAST CORPORATIONCMCSV | 179 | $24.7M |
| 12 |  MERCK & CO INCMRK | 14 | $24.0M |
| 13 |  SOUTHERN COMPANYSO | 53 | $23.9M |
| 14 |  GOOGLE CLIENT SERVICES LLCGOOGL | 79 | $22.6M |
| 15 |  APPLE INCAAPL | 9 | $22.1M |
| 16 |  T-MOBILE USA INC.TMUS | 121 | $21.0M |
| 17 |  UNITEDHEALTH GROUP INCUNH | 19 | $20.4M |
| 18 |  VERIZON COMMUNICATIONS INC AND VARIOUS SUBSIDIARIESVZ | 40 | $20.1M |
| 19 |  OCCIDENTAL PETROLEUM CORPORATIONOXY | 30 | $19.7M |
| 20 |  MICROSOFT CORPORATIONMSFT | 103 | $18.8M |
| 21 |  QUALCOMM INCORPORATEDQCOM | 40 | $17.2M |
| 22 |  GENERAL DYNAMICS CORPGD | 11 | $17.0M |
| 23 |  BOEING COMPANYBA | 23 | $16.9M |
| 24 | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)CI | 13 | $16.9M |
| 25 |  ORACLE CORPORATIONORCL | 58 | $16.7M |
🎯 Top Lobbied Tickers
| # | Ticker | Filings | Total $ |
|---|---|---|---|
| 1 | META Meta Platforms Inc. | 129 | $50.2M |
| 2 | PFE Pfizer Inc. | 87 | $48.6M |
| 3 | GM General Motors Company | 103 | $48.4M |
| 4 | V Visa Inc. | 46 | $37.7M |
| 5 | AMZN Amazon.com Inc. | 80 | $35.3M |
| 6 | LMT Lockheed Martin Corporation | 88 | $29.4M |
| 7 | FDX FedEx Corporation | 82 | $28.3M |
| 8 | LLY Eli Lilly and Company | 83 | $28.1M |
| 9 | AMGN Amgen Inc. | 95 | $28.0M |
| 10 | MRK Merck & Co. Inc. | 92 | $27.5M |
| 11 | AAPL Apple Inc. | 64 | $26.8M |
| 12 | GOOGL Alphabet Inc. Class A | 123 | $26.6M |
| 13 | MO | 164 | $26.2M |
| 14 | SO Southern Company | 108 | $26.1M |
| 15 | UNH UnitedHealth Group Inc. | 67 | $23.9M |
| 16 | VZ Verizon Communications Inc. | 116 | $23.8M |
| 17 | TMUS | 159 | $22.7M |
| 18 |  CHTR | 137 | $22.6M |
| 19 | GD General Dynamics Corporation | 127 | $22.5M |
| 20 |  TAT&T Inc. | 134 | $21.6M |
| 21 | ORCL Oracle Corporation | 132 | $20.6M |
| 22 | CMCSA Comcast Corporation | 141 | $20.4M |
| 23 | CI The Cigna Group | 64 | $19.9M |
| 24 | OXY Occidental Petroleum Corporation | 36 | $19.9M |
| 25 | MSFT Microsoft Corporation | 122 | $19.2M |
🆕 Filtered Filings · INCYTE CORPORATION
clear filters| Date | Ticker | Client | Registrant | Amount | Issue |
|---|---|---|---|---|---|
| 2026-04-20 | INCY | INCYTE CORPORATION | INCYTE CORPORATION | $480K | H.R. 946 / S. 1862, Orphan Cures Act implementation H.R. 1262 Give Kids a Chance Act Issues related to Medicaid rebates Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology |
| 2026-04-20 | INCY | INCYTE CORPORATION | AVENUE SOLUTIONS | $60K | Issues related to 340b; Public Law No: 119-75, Consolidated Appropriations Act, 2026 - issues related to expiring healthcare extenders and expiring Advanced Premium Tax Credits (APTC) Issues related to Medicaid rebates; Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to CMMI demos (Guarding U.S. Medicare Against Rising Drug Costs (GUARD) and Global Benchmark for Efficient Drug Pricing (GLOBE)) |
| 2026-04-18 | INCY | INCYTE CORPORATION | TIBER CREEK GROUP | $80K | Issues related to Medicare Part D and Part B Pricing Reform; Issues related to Medicaid Rebates; Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act. |
| 2026-04-18 | INCY | INCYTE CORPORATION | W STRATEGIES, LLC | $60K | Education around access to innovative therapies in dermatology. Issues related to Medicaid Drug Rebate program rule. Public Law 119-21: One Big Beautiful Bill Act, as it relates to H.R.946 - ORPHAN Cures Act. Issues related to drug pricing. |
| 2026-04-17 | INCY | INCYTE CORPORATION | CHECKMATE GOVERNMENT RELATIONS | $110K | Issues relating to CMS coverage and reimbursement policies. |
| 2026-04-17 | INCY | INCYTE CORPORATION | LMH STRATEGIC SOLUTIONS | $50K | Healthcare-related legislative and regulatory issues impacting the biotechnology, pharmaceutical, and consumer health industry. Healthcare-related legislative and regulatory issues impacting the biotechnology, pharmaceutical, and consumer health industry. |
| 2026-01-20 | INCY | INCYTE CORPORATION | INCYTE CORPORATION | $530K | H.R. 946/S. 1862, Orphan Cures Act implementation H.R. 1262 Give Kids a Chance Act Issues related to Medicaid rebates Issues related to Medicaid coverage of new drugs Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology |
| 2026-01-20 | INCY | INCYTE CORPORATION | TIBER CREEK GROUP | $80K | Issues related to Medicare Part D and Part B Pricing Reform; Issues related to Medicaid Rebates; Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act. |
| 2026-01-20 | INCY | INCYTE CORPORATION | CHECKMATE GOVERNMENT RELATIONS | $70K | Issues relating to CMS coverage and reimbursement policies. |
| 2026-01-20 | INCY | INCYTE CORPORATION | W STRATEGIES, LLC | $60K | Education around access to innovative therapies in dermatology. Issues related to the 340(b)program. Issues related to Medicaid Drug Rebate program rule. Public Law 119-21: One Big Beautiful Bill Act, as it relates to H.R.946 - ORPHAN Cures Act. |
| 2026-01-20 | INCY | INCYTE CORPORATION | AVENUE SOLUTIONS | $60K | Issues related to 340b; Expiring healthcare extenders; Issues related to Priority Review Voucher (PRV) program Issues related to Medicaid rebates; Issues related to Most Favored Nation (MFN) drug pricing proposal |
| 2026-01-12 | INCY | INCYTE CORPORATION | LMH STRATEGIC SOLUTIONS | $70K | Prescription drug payment reform. Pharmaceutical supply chain. General Medicare and Medicaid Issues. |
| 2025-12-22 | INCY | INCYTE CORPORATION | CHECKMATE GOVERNMENT RELATIONS | $0 | Issues relating to CMS coverage and reimbursement policies. |
| 2025-10-20 | INCY | INCYTE CORPORATION | INCYTE CORPORATION | $330K | H.R. 946/S. 1862, Orphan Cures Act implementation H.R. 1262 Give Kids a Chance Act Issues related to Medicaid rebates Issues related to Medicaid coverage of new drugs Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology |
| 2025-10-20 | INCY | INCYTE CORPORATION | LMH STRATEGIC SOLUTIONS | $70K | Prescription drug payment reform. Pharmaceutical supply chain. General Medicare and Medicaid Issues. |
| 2025-10-20 | INCY | INCYTE CORPORATION | W STRATEGIES, LLC | $60K | Education around access to innovative therapies in dermatology. Issues related to the 340(b)program. Issues related to Medicaid Drug Rebate program rule. Public Law 119-21: One Big Beautiful Bill Act, as it relates to H.R.946 - ORPHAN Cures Act. |
| 2025-10-20 | INCY | INCYTE CORPORATION | AVENUE SOLUTIONS | $60K | Issues related to 340b; Expiring healthcare extenders Issues related to Medicaid rebates; Issues related to Most Favored Nation (MFN) drug pricing proposal |
| 2025-10-19 | INCY | INCYTE CORPORATION | TIBER CREEK GROUP | $80K | Issues related to Medicare Part D and Part B Pricing Reform; Issues related to Medicaid Rebates; Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act. |
| 2025-07-21 | INCY | INCYTE CORPORATION | INCYTE CORPORATION | $520K | H.R. 946/S. 1862, Orphan Cures Act H.R. 1262, Give Kids a Chance Act Issues related to Medicaid rebates Issues related to Medicaid coverage of new drugs Issues related to implementation of the Inflation Reduction Act Issues related to drug cost and pricing Education around access to innovative therapies in dermatology |
| 2025-07-21 | INCY | INCYTE CORPORATION | AVENUE SOLUTIONS | $60K | Issues related to 340b; Health care issues in H.R. 1, To provide for reconciliation pursuant to title II of H. Con. Res. 14 (Public Law No: 119-21) Issues related to Medicaid rebates; H.R. 946/S. 1862, Orphan Cures Act; Health care issues H.R. 1, To provide for reconciliation pursuant to title II of H. Con. Res. 14 (Public Law No: 119-21); Issues related to Most Favored Nation (MFN) drug pricing proposal |
| 2025-07-19 | INCY | INCYTE CORPORATION | TIBER CREEK GROUP | $80K | Issues related to Medicare Part D and Part B Pricing Reform; Issues related to Medicaid Rebates; Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act. |
| 2025-07-18 | INCY | INCYTE CORPORATION | W STRATEGIES, LLC | $60K | Education around access to innovative therapies in dermatology. Issues related to the 340(b)program. Issues related to Medicaid Drug Rebate program rule. H.R.1 - One Big Beautiful Bill Act, as it relates to H.R.946 - ORPHAN Cures Act. |
| 2025-07-15 | INCY | INCYTE CORPORATION | LMH STRATEGIC SOLUTIONS | $0 | Prescription drug payment reform. Pharmaceutical supply chain. General Medicare and Medicaid Issues. Prescription drug payment reform. Pharmaceutical supply chain. General Medicare and Medicaid Issues. |
| 2025-04-21 | INCY | INCYTE CORPORATION | INCYTE CORPORATION | $240K | HR 946, Orphan Cures Act HR 1262, Give Kids a Chance Act of 2025 Issues related to Medicaid rebates Education around access to innovative therapies in dermatology |
| 2025-04-21 | INCY | INCYTE CORPORATION | AVENUE SOLUTIONS | $60K | Issues related to 340b Issues related to Inflation Reduction Act of 2022 (PL 117-169) implementation; Issues related to Medicaid rebates |
| 2025-04-18 | INCY | INCYTE CORPORATION | TIBER CREEK GROUP | $70K | Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to Medicare Part D and Part B Pricing Reform; Issues related to Medicaid Rebates; Issues related to H.R. 946 - ORPHAN Cures Act. |
| 2025-04-18 | INCY | INCYTE CORPORATION | W STRATEGIES, LLC | $60K | Education around access to innovative therapies in dermatology. Issues related to the 340(b)program. Issues related to Medicaid Drug Rebate program rule. H.R.5376 - Implementation of Inflation Reduction Act. |
| 2025-02-21 | INCY | INCYTE CORPORATION | INCYTE CORPORATION | $350K | Issues: Issues related to Medicaid rebates, H.R. 3433 The Give Kids a Chance Act |
| 2025-01-21 | INCY | INCYTE CORPORATION | INCYTE CORPORATION | $240K | Issues: Issues related to Medicaid rebates, H.R. 3433 The Give Kids a Chance Act |
| 2025-01-21 | INCY | INCYTE CORPORATION | W STRATEGIES, LLC | $60K | Education around access to innovative therapies in dermatology. Issues related to the 340(b)program. Issues related to Medicaid Drug Rebate program rule. H.R.5376 - Implementation of Inflation Reduction Act. |
| 2025-01-21 | INCY | INCYTE CORPORATION | AVENUE SOLUTIONS | $60K | Issues related to 340b; Issues related to Tricare coverage for Vitiligo; H.R. 10545, American Relief Act, 2025 Issues related to Inflation Reduction Act of 2022 (PL 117-169) implementation; Issues related to Medicaid coverage for Vitiligo; Issues related to healthcare access, quality and costs; Issues related to Medicaid rebates |
| 2025-01-19 | INCY | INCYTE CORPORATION | TIBER CREEK GROUP | $60K | Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); Issues relating to Medicare Part D and Part B Pricing Reform; Issues related to Medicaid Rebates. |